Evaluation of the role of hexokinase type II in cellular proliferation and apoptosis using human hepatocellular carcinoma cell lines

Journal of Nuclear Medicine

Volumn 50, Issue 9, 2009, Pages 1525-1532

  Keun, Jae Ahn ^a   Hee, Sung Hwang ^b   Jeon, Han Park ^a   Seong, Hye Bang ^a   Won, Jun Kang ^a   Yun, Mijin ^a   Jong, Doo Lee ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Hallym University Sacred Heart Hospital   (South Korea)

Author keywords

18F FDG uptake; Hepatocellular carcinoma; Hexokinase; PI3K Akt signaling; Prognosis

Indexed keywords

ADENOSINE TRIPHOSPHATE; CISPLATIN; FLUORODEOXYGLUCOSE F 18; GLUCOSE 6 PHOSPHATASE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; HEXOKINASE; HEXOKINASE TYPE 2; HEXOKINASE TYPE 3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LACTIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG UPTAKE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MEASUREMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; FLUORODEOXYGLUCOSE F18; HEXOKINASE; HUMANS; LIVER NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 69449092738     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.060780     Document Type: Article

References (39)

1. Young H, Baum R, Cremerius U, et al. Measurement of clinical and sub-clinical tumour response using [F-18] fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer. 1999;35:1773-1782. (Pubitemid 29512308)
2. 18F-fluoro-2-deoxy-glucose- positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol. 1999;17:3201-3206.
3. Lee JD, Yun M, Lee JM, et al. Analysis of gene expression profiles of hepatocellular carcinomas with regard to F-18-FDG uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging. 2004;31:1621-1630. (Pubitemid 40104608)
4. 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43:173-180.
5. 18F-FDG uptake. J Nucl Med. 2005;46:1753-1759.
6. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
7. Bustamante E, Pedersen PL. High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc Natl Acad Sci USA. 1977;74:3735-3739. (Pubitemid 8189957)
8. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet. 2005;39:359-407.
9. Bustamante E, Morris HP, Pedersen PL. Energy metabolism of tumor cells: requirement for a form of hexokinase with a propensity for mitochondrial binding. J Biol Chem. 1981;256:8699-8704. (Pubitemid 12254812)
10. Arora KK, Pedersen PL. Functional significance of mitochondrial bound hexokinase in tumor cell metabolism: evidence for preferential phosphorylation of glucose by intramitochondrially generated ATP. J Biol Chem. 1988;263:17422-17428.
11. Rempel A, Mathupala SP, Griffin CA, Hawkins AL, Pedersen PL. Glucose catabolism in cancer cells: amplification of the gene encoding type II hexokinase. Cancer Res. 1996;56:2468-2471. (Pubitemid 26170674)
12. Golshani-Hebroni SG, Bessman SP. Hexokinase binding to mitochondria: a basis for proliferative energy metabolism. J Bioenerg Biomembr. 1997;29:331-338.
13. Pastorino JG, Hoek JB. Hexokinase II: the integration of energy metabolism and control of apoptosis. Curr Med Chem. 2003;10:1535-1551.
14. Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol. 2003;206:2049-2057.
15. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25:4633-4646.
16. Pastorino JG, Shulga N, Hoek JB. Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem. 2002;277:7610-7618. (Pubitemid 34953160)
17. Roh MS, Jeong JS, Kim YH, Kim MC, Hong SH. Diagnostic utility of Glut 1 in the differential diagnosis of liver carcinomas. Hepatogastroenterology. 2004;51:1315-1318.
18. Zimmerman RL, Fogt F, Burke M, Murakata LA. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesion and hepatocellular carcinoma. Oncol Rep. 2002;9:689-692.
19. Chen YT, Stockert E, Chen Y, et al. Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Proc Natl Acad Sci USA. 1994;91:1004-1008. (Pubitemid 24048497)
20. Robey RB, Hay N. Mitochondrial hexokinases: novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene. 2006;25:4683-4696. (Pubitemid 44187618)
21. Rigo P, Paulus P, Kaschten BJ, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med. 1996;23:1641-1674. (Pubitemid 27023063)
22. Schroder O, Trojan J, Zeuzem S, Baum RP. Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection. Nuklearmedizin. 1998;37:279-285. (Pubitemid 29010883)
23. Whitesell RR, Ardehali H, Beechem JM, et al. Compartmentalization of transport and phosphorylation of glucose in a hepatoma cell line. Biochem J. 2005;386:245-253. (Pubitemid 40343781)
24. Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. Annu Rev Med. 2002;53:89-112. (Pubitemid 34177873)
25. Aloj L, Caraco C, Jagoda E, Eckelman WC, Neumann RD. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res. 1999;59:4709-4714. (Pubitemid 29428980)
26. Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta. 2002;1555:14-20. (Pubitemid 35245999)
27. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 2001;15:1406-1418. (Pubitemid 32524647)
28. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med. 2008;49(suppl):24S-42S. (Pubitemid 351948035)
29. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005;9:59-71.
30. Paez J, Sellers WR. PI3K/PTEN/AKT pathway: a critical mediator of oncogenic signaling. Cancer Treat Res. 2003;115:145-167.
31. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4:988-1004.
32. Filippa N, Sable CL, Filloux C, Hemmings B, Van Obberghen E. Mechanism of protein kinase B activation by cyclic AMP-dependent protein kinase. Mol Cell Biol. 1999;19:4989-5000. (Pubitemid 29289538)
33. Hardie DG. The AMP-activated protein kinase pathway: new players upstream and downstream. J Cell Sci. 2004;117:5479-5487.
34. Kuhajda FP. AMP-activated protein kinase and human cancer: cancer metabolism revisited. Int J Obes (Lond). 2008;32(suppl):S36-S41.
35. Toker A. mTOR and Akt signaling in cancer: SGK cycles in. Mol Cell. 2008;31:6-8.
36. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004;10:594-601. (Pubitemid 38796850)
37. Balsara BR, Pei J, Mitsuuchi Y, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis. 2004;25:2053-2059. (Pubitemid 39534841)
38. Itoh N, Semba S, Ito M, Takeda H, Kawata S, Yamakawa M. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer. 2002;94:3127-3134. (Pubitemid 34670495)
39. Segrelles C, Ruiz S, Perez P, et al. Functional roles of Akt signaling in mouse skin tumorigenesis. Oncogene. 2002;21:53-64. (Pubitemid 34076378)